SAN DIEGO, July 24, 2025 /PRNewswire/ -- In emergency care settings, every second counts. Early drug detection not only improves clinical decision-making, it can be the difference between life and death. But with the rise of counterfeit medications and drug combinations that are more potent and less predictable, emergency departments must adapt faster than ever.
QuidelOrtho Science Bytes Episode 49 "How Urgent Diagnostic Testing Can Help Prevent Drug Overdose Deaths," addresses the escalating complexities of substance use detection and care in emergency departments across the country. The episode features Vonda McAllister, Director of Global Product Management at QuidelOrtho, whose deep experience in diagnostics and toxicology provides critical perspective on the clinical and societal impacts of today's most dangerous drug trends.
Subscribe to QuidelOrtho Science Bytes
Episode Highlights:
Key Quotes:
Vonda McCallister, Director of Global Product Management, QuidelOrtho
"As overdose presentations become more complex, continuous monitoring, comprehensive toxicology screening and clinical vigilance are essential tools in the fight against this crisis."
About QuidelOrtho Science Bytes
Science Bytes is a monthly podcast that delivers diagnostic insights and innovation updates from QuidelOrtho, helping healthcare providers stay informed and prepared. Episode 49 is now available on all major podcast platforms.
For more information and to listen to the full episode, visit www.quidelortho.com/sciencebytes.
About QuidelOrtho Corporation
QuidelOrtho Corporation (Nasdaq: QDEL) is a global provider of innovative diagnostic testing solutions. From infectious diseases to cardiac biomarkers to women's health, QuidelOrtho transforms the power of diagnostics into a healthier future through science, innovation, and accessibility. Learn more at www.quidelortho.com.
Source: QuidelOrtho Corporation
Investor Contact: Juliet Cunningham Vice President, Investor Relations This email address is being protected from spambots. You need JavaScript enabled to view it. | Media Contact: D. Nikki Wheeler Senior Director, Corporate Communications This email address is being protected from spambots. You need JavaScript enabled to view it. |
Last Trade: | US$26.54 |
Daily Change: | 0.23 0.87 |
Daily Volume: | 403,189 |
Market Cap: | US$1.800B |
September 22, 2025 August 19, 2025 August 13, 2025 August 05, 2025 |
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MOREC4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREEnd of content
No more pages to load